293291-20-0

Upstream product

• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 127106-74-5 (S)-[3-diazo-1-(4-nitrobenzyl)-2-oxo-propyl]carbamic acid tert-butyl ester 

Downstream Products

• 960157-85-1 (1S)-2-(4-nitrophenyl)-1-(2-phenyl-1,3-thiazol-4-yl)ethan-1-amine hydrobromide 
• 1000394-51-3 (S)-2-(4-nitrophenyl)-1-(2-(thiophen-2-yl)thiazol-4-yl)ethan-1-amine hydrobromide 
• 1000395-37-8 (S)-2-(4-nitrophenyl)-1-[(thiophen-2-yl)oxazol-4-yl]ethanamine hydrobromide salt 
• 960157-87-3 (S)-4-(1-isothiocyanato-2-(4-nitrophenyl)ethyl)-2-phenylthiazole 
• 960157-89-5 (S)-5-methyl-N-[2-(4-nitrophenyl)-1-(2-phenylthiazol-4-yl)ethyl]-1,3,4-thiadiazol-2-amine 
• 960157-91-9 (S)-4-[2-(5-methyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]phenylsulfamic acid ammonium salt 
• 1000394-52-4 2-(3-chlorophenyl)-N-{(S)-2-(4-nitrophenyl)-1-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}acetamide 
• 1235330-55-8 N-{4-[(2S)-2-[2-(3-chlorophenyl)acetamido]-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl]phenyl}sulfamic acid ammonium salt 
• 1000394-83-1 1-benzyl-3-{(S)-2-(4-nitrophenyl)-1-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}urea 
• 1235330-67-2 4-{(S)-2-(3-benzylureido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid ammonium salt 
• 1000394-85-3 (S)-N-{2-(4-nitrophenyl)-1-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}-1-phenylmethanesulfonamide 
• 1000395-00-5 (S)-methyl 5-[1-(2-phenylthiazol-4-yl)-2-(4-nitrophenyl)ethylamino]thiazole-4-carboxylate 
• 1235330-73-0 (S)-4-(2-(2-phenylthiazol-4-yl)2-(4-(methoxycarbonyl)thiazole-5-ylamino)ethyl)phenylsulfamic acid ammonium salt 
• 1000395-17-4 (S)-1-[1-(thiophen-2-ylthiazol-4-yl)-2-(4-nitrophenyl)ethyl]thiourea 

Relevant academic research and scientific papers

THIADIAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF OCULAR EDEMA

Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular d

METHODS FOR TREATING VASCULAR LEAK SYNDROME

Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease. Yet further disclosed are methods for treating rena

COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility ar

COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.

METHODS FOR TREATING VASCULAR LEAK SYNDROME

Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal c

Human protein tyrosine phosphatase inhibitors and methods of use

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phos